Ignite Creation Date:
2024-05-06 @ 3:15 PM
Last Modification Date:
2024-10-26 @ 1:46 PM
Study NCT ID:
NCT04570332
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-01-29
First Post:
2020-09-22
Brief Title:
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Sponsor:
Highlight Therapeutics
Organization:
Highlight Therapeutics
Organization Data
Organization:
Highlight Therapeutics
Class:
INDUSTRY
Study ID:
BOT112-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Highlight Therapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |